Join
Live feed
·
PRReleasevia Quantisnow
Adagene Inc. logo

Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response

ByQuantisnow·Wall Street's wire, on your screen.
ADAG· Adagene Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ADAG (Adagene Inc.) and more on Quantisnow.